Review
Obstetrics & Gynecology
Alexander Katalinic, Lee P. Shulman, Jerome F. Strauss, Juan A. Garcia-Velasco, John N. van den Anker
Summary: No evidence supports the suggestion that using dydrogesterone in the first trimester increases the risk of fetal abnormalities. Previous studies suggesting a link have been retracted. A scoping review and meta-analysis found no plausible mechanism for this potential causality.
REPRODUCTIVE BIOMEDICINE ONLINE
(2022)
Review
Obstetrics & Gynecology
Ameet Patki
Summary: The advent of the frozen-thawed embryo transfer (FET) technique has significantly improved the clinical outcomes of in vitro fertilization (IVF). Oral dydrogesterone may potentially become a preferred drug for luteal phase support in millions of women undergoing IVF, as it has a higher bioavailability and specificity for progesterone receptors compared to other options. Clinical studies have demonstrated that oral dydrogesterone is non-inferior to micronized vaginal progesterone in terms of efficacy and safety.
REPRODUCTIVE SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Laura Jeschke, Clarisa Guillermina Santamaria, Nicole Meyer, Ana Claudia Zenclussen, Julia Bartley, Anne Schumacher
Summary: The study showed that early-pregnancy administration of dydrogesterone does not interfere with placental and fetal development, fetal-maternal circulation, or fetal survival. Dydrogesterone-exposed offspring grew normally and were fertile, though male offspring showed altered sperm parameters.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Obstetrics & Gynecology
Diana Man Ka Chan, Ka Wang Cheung, Jennifer Ka Yee Ko, Sofie Shuk Fei Yung, Shui Fan Lai, Mei Ting Lam, Dorothy Yuet Tao Ng, Vivian Chi Yan Lee, Raymond Hang Wun Li, Ernest Hung Yu Ng
Summary: The use of oral progestogen in women with threatened miscarriage in the first trimester did not reduce the miscarriage rate before 20 weeks when compared with placebo.
HUMAN REPRODUCTION
(2021)
Article
Endocrinology & Metabolism
Virginie Simon, Geoffroy Robin, Laura Keller, Camille Ternynck, Sophie Jonard, Camille Robin, Christine Decanter, Pauline Plouvier
Summary: The addition of intramuscular progesterone injection to oral dydrogesterone as luteal phase support does not significantly affect the outcomes of in vitro fertilization (IVF) when a single fresh blastocyst transfer is performed.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Asher Bashiri, Gabi Galperin, Atif Zeadna, Yael Baumfeld, Tamar Wainstock
Summary: This retrospective cohort study compared the live birth rates of women with and without progesterone treatment for recurrent pregnancy loss (RPL). The results showed that progesterone treatment was independently associated with a higher rate of live births in RPL patients. Further studies with larger sample sizes are recommended to confirm these findings.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Obstetrics & Gynecology
Jade E. Bilardi, Meredith Temple-Smith
Summary: Miscarriage and recurrent miscarriage have profound and prolonged psychological impacts, yet support for miscarriage remains inadequate. Acknowledgment and validation of grief, provision of information, and addressing the discrepancy between bereavement care offered and desired are important steps to ameliorate the impact. Collecting national miscarriage data and establishing national research funding priorities would allow for a better understanding of the socioeconomic cost and burden of miscarriage and enable targeted research for public health benefit.
FERTILITY AND STERILITY
(2023)
Article
Obstetrics & Gynecology
L. A. Linehan, I. San Lazaro Campillo, M. Hennessy, C. Flannery, K. O'Donoghue
Summary: This study focused on the subsequent reproductive outcomes of women with recurrent miscarriage (RM), finding that 77% of women had a subsequent pregnancy, with a livebirth rate of 63%. The study highlighted the associations between factors such as age, smoking, and parental balanced translocations with the likelihood of further pregnancy.
HUMAN REPRODUCTION OPEN
(2022)
Article
Endocrinology & Metabolism
Angela Vidal, Carolin Dhakal, Nathalie Werth, Jurgen Michael Weiss, Dirk Lehnick, Alexandra Sabrina Kohl Schwartz
Summary: This study compared the reproductive outcomes and tolerability of five different regimens of hormonal luteal phase support in frozen embryo transfer cycles. The results showed that the clinical pregnancy rate and live birth rate were higher in the oral dydrogesterone-only group and the dydrogesterone + micronized progesterone gel group, indicating that oral dydrogesterone may be a promising option for luteal phase support.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Obstetrics & Gynecology
Pirkko Peuranpaea, Tiina Holster, Schahzad Saqib, Ilkka Kalliala, Aila Tiitinen, Anne Salonen, Hanna Hautamaki
Summary: This study found that dysbiosis of the endometrial and vaginal microbiota is associated with recurrent pregnancy loss and may represent a novel risk factor for pregnancy loss. Specifically, there was a decrease in relative abundance of Lactobacillus crispatus in endometrial samples and an increase in Gardnerella vaginalis abundance in the RPL group.
REPRODUCTIVE BIOMEDICINE ONLINE
(2022)
Article
Obstetrics & Gynecology
Lucas A. McLindon, Gabriel James, Michael M. Beckmann, Julia Bertolone, Kassam Mahomed, Monica Vane, Teresa Baker, Monique Gleed, Sandra Grey, Linda Tettamanzi, Ben Willem J. Mol, Wentao Li
Summary: In women with threatened miscarriage, progesterone supplementation until the completion of the first trimester of pregnancy does not increase the probability of live birth.
HUMAN REPRODUCTION
(2023)
Article
Obstetrics & Gynecology
Haley G. Genovese, Dana B. Mcqueen
Summary: This manuscript reports on the prevalence of early pregnancy loss and discusses the impact of improved pregnancy diagnosis, as well as the influence of increased age and body mass index at first birth.
FERTILITY AND STERILITY
(2023)
Article
Oncology
Caiyu Lou, Caiwen Wang, Qiang Zhao, Fenyuan Jin
Summary: The study found no significant difference in clinical symptom relief time and miscarriage prevention rate between dydrogesterone treatment and progesterone treatment for threatened miscarriage due to corpus luteum insufficiency. However, dydrogesterone treatment significantly upregulated sex hormone levels and reduced preterm birth rate, postpartum hemorrhage rate, and adverse effects after 4 weeks of treatment. XGBoost algorithm analysis showed that dydrogesterone treatment was associated with lower rates of preterm birth, postpartum hemorrhage, and adverse effects, indicating its improved efficacy and safety compared to progesterone.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Kai Chen, Xiaoxia Liu, Xianhua Meng, Hui Li, Chenchen Yang, Xiaohong Wang
Summary: This meta-analysis evaluated the effectiveness and safety of combining Gushen Antai Pills with dydrogesterone in treating threatened miscarriage. The results showed that the combination therapy significantly reduced the incidence of early pregnancy loss, alleviated clinical symptoms, and improved hormone levels compared to dydrogesterone alone. However, further randomized controlled trials with rigorous design are needed to confirm these findings due to limitations and bias in the included studies.
FRONTIERS IN PHARMACOLOGY
(2023)
Editorial Material
Obstetrics & Gynecology
Dominique de Ziegler, Rene F. Frydman
Summary: Recurrent pregnancy loss (RPL) is defined as two to three spontaneous pregnancy terminations before 12 weeks of gestation, potentially caused by factors like gamete quality, uterine issues, endometrial receptivity alterations, immunologic factors, and thrombophilia.
FERTILITY AND STERILITY
(2021)